Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Top Cited Papers
- 1 February 2016
- journal article
- review article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 18 (S2), S2-3
- https://doi.org/10.1089/dia.2015.0417
Abstract
Continuous glucose monitoring (CGM) provides information unattainable by intermittent capillary blood glucose, including instantaneous real-time display of glucose level and rate of change of glucose, alerts and alarms for actual or impending hypo- and hyperglycemia, “24/7” coverage, and the ability to characterize glycemic variability. Progressively more accurate and precise, reasonably unobtrusive, small, comfortable, user-friendly devices connect to the Internet to share information and are sine qua non for a closed-loop artificial pancreas. CGM can inform, educate, motivate, and alert people with diabetes. CGM is medically indicated for patients with frequent, severe, or nocturnal hypoglycemia, especially in the presence of hypoglycemia unawareness. Surprisingly, despite tremendous advances, utilization of CGM has remained fairly limited to date. Barriers to use have included the following: (1) lack of Food and Drug Administration approval, to date, for insulin dosing (“nonadjuvant use”) in the United States and for use in hospital and intensive care unit settings; (2) cost and variable reimbursement; (3) need for recalibrations; (4) periodic replacement of sensors; (5) day-to-day variability in glycemic patterns, which can limit the predictability of findings based on retrospective, masked “professional” use; (6) time, implicit costs, and inconvenience for uploading of data for retrospective analysis; (7) lack of fair and reasonable reimbursement for physician time; (8) inexperience and lack of training of physicians and other healthcare professionals regarding interpretation of CGM results; (9) lack of standardization of software methods for analysis of CGM data; and (10) need for professional medical organizations to develop and disseminate additional clinical practice guidelines regarding the role of CGM. Ongoing advances in technology and clinical research have addressed several of these barriers. Use of CGM in conjunction with an insulin pump with automated suspension of insulin infusion in response to actual observed or predicted hypoglycemia, as well as progressive refinement of closed-loop systems, is expected to dramatically enhance the clinical utility and utilization of CGM.Keywords
This publication has 50 references indexed in Scilit:
- Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial PancreasThe Journal of Pediatrics, 2015
- Hypoglycemia Reduction and Accuracy of Continuous Glucose MonitoringDiabetes Technology & Therapeutics, 2015
- Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing KetosisDiabetes Care, 2015
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Multinight “Bedside” Closed-Loop Control for Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2015
- The Benefits, Limitations, and Cost-Effectiveness of Advanced Technologies in the Management of Patients With Diabetes MellitusJournal of Diabetes Science and Technology, 2015
- A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2014
- Accuracy of the Sof-Sensor Glucose Sensor with the iPro Calibration AlgorithmJournal of Diabetes Science and Technology, 2012
- Clinical Interpretation of Indices of Quality of Glycemic Control and Glycemic VariabilityPostgraduate Medicine, 2011
- Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile AnalysisDiabetes Technology & Therapeutics, 2008